Skip to main content

Treatments for Rosacea

Because rosacea symptoms can vary substantially from person to person, treatment must be tailored by a dermatologist for each individual.

Galderma, a leader in skin health, is proud to offer a variety of rosacea prescription treatments: one that targets and treats the bumps and blemishes of rosacea from the inside; one that treats the bumps and blemishes of rosacea from the outside; and one that provides quick relief from facial redness.

Soolantra (Ivermectin) Once-daily Cream, 1%

Treating Rosacea From The Outside SOOLANTRA® (ivermectin) Cream, 1%

SOOLANTRA Cream is a gentle, once-daily topical prescription treatment. If you are looking to fight rosacea bumps and blemishes with the #1 branded topical rosacea treatment in the US, SOOLANTRA Cream may be the right treatment for you.

Learn More

Oracea (doxycycline, USP) Once-daily 40 mg Capsules

Treating Rosacea From The Inside ORACEA® (doxycycline, USP) 40 mg* Capsules

ORACEA Capsules are different because they treat rosacea from the inside out. This once a day, non-antibiotic dose prescription medication treats inflammation below the skin to reduce the bumps and blemishes of rosacea. 

Learn More

Mirvaso (brimonidine) topical gel, 0.33%

Treating Rosacea For Redness Relief MIRVASO® (brimonidine) topical gel, 0.33%

If you have persistent (nontransient) facial redness associated with rosacea, MIRVASO Topical Gel may be an option for you, because it relieves redness of rosacea that may last up to 12 hours. 

Learn More

Active Ingredients

Our innovative product range allows us to advance skincare treatment with science-based options over the course of people’s lives. Consult with your dermatologist to see if these treatment options may be right for you.

Ivermectin

The active ingredient in SOOLANTRA® (ivermectin) Cream, 1% is ivermectin, which is reported to have anti-parasitic and anti-inflammatory properties. SOOLANTRA Cream effectively improves rosacea bumps and blemishes with a powerful medication that is formulated with a gentle moisturizing base.

In a 12-week clinical trial, subjects using SOOLANTRA Cream saw a reduction of symptoms in just 2 weeks. Many subjects saw their skin improve in appearance over the course of the study.

Learn More

Doxycycline, USP

The active ingredient in ORACEA® (doxycycline, USP) 40 mg* Capsules is doxycycline, but unlike traditional antibiotic doses of doxycycline, the low-dose formulation of ORACEA Capsules does not work by killing bacteria. Instead, it reduces the bumps and blemishes of rosacea because of its anti-inflammatory properties. That’s important because rosacea is a chronic inflammatory skin condition—not a bacterial infection.

ORACEA Capsules are packed with enough doxycycline to reduce the inflammatory lesions associated with rosacea.

Learn More

Brimonidine

MIRVASO® (brimonidine) topical gel, 0.33% is an alpha-adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.

MIRVASO topical gel is the first FDA-approved treatment developed and indicated for persistent (nontransient) facial redness of rosacea. Facial redness is a common symptom of rosacea, a skin condition that affects an estimated 16 million Americans.

Learn More

Important Safety Information for ORACEA® (doxycycline, USP) 40 mg* Capsules

Indication: ORACEA Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established. Click here to view the full prescribing information for ORACEA Capsules.

*30 mg immediate release & 10 mg delayed release beads

Important Safety Information for SOOLANTRA® (ivermectin) Cream, 1%

Indication: SOOLANTRA Cream is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence ≤ 1 %) included skin burning sensation and skin irritation. Click here to view the full prescribing information for SOOLANTRA Cream.

Important Safety Information for MIRVASO® (brimonidine) topical gel, 0.33%†

Indication: MIRVASO Gel is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha‐2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use. Click here to view full prescribing information for MIRVASO Gel.

†Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Select a Brand for Prescribing Information:

*30 mg immediate release & 10 mg delayed release beads
†Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.